Hookipa Pharma (NASDAQ:HOOK) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Hookipa Pharma (NASDAQ:HOOK) from a hold rating to a sell rating in a research note published on Wednesday morning, Zacks.com reports.

According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “

A number of other research analysts have also commented on the company. Svb Leerink assumed coverage on Hookipa Pharma in a research report on Monday, May 13th. They issued an outperform rating and a $20.00 price objective on the stock. Leerink Swann assumed coverage on Turning Point Therapeutics in a research report on Monday, May 13th. They issued an outperform rating and a $42.00 price objective on the stock. Royal Bank of Canada increased their price objective on NVIDIA to $200.00 and gave the company an outperform rating in a research report on Monday, May 13th. Finally, Bank of America upgraded Copa from a neutral rating to a buy rating in a research report on Monday, May 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Hookipa Pharma currently has an average rating of Buy and an average target price of $20.00.



Shares of HOOK opened at $7.54 on Wednesday. The company has a fifty day moving average price of $7.58. Hookipa Pharma has a 52 week low of $6.06 and a 52 week high of $14.76.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings data on Monday, May 20th. The company reported ($9.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($8.85). The business had revenue of $2.24 million during the quarter, compared to analysts’ expectations of $0.50 million. On average, equities research analysts predict that Hookipa Pharma will post -2.14 earnings per share for the current fiscal year.

In related news, major shareholder Sofinnova Capital Vi Fcpr purchased 357,142 shares of Hookipa Pharma stock in a transaction dated Tuesday, April 23rd. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $4,999,988.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Bros. Advisors Lp Baker purchased 892,857 shares of Hookipa Pharma stock in a transaction dated Tuesday, April 23rd. The stock was bought at an average price of $14.00 per share, for a total transaction of $12,499,998.00. The disclosure for this purchase can be found here.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Further Reading: Federal Reserve

Get a free copy of the Zacks research report on Hookipa Pharma (HOOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.